Structure of the Market for Antimalarials in Sub-Saharan Africa
Stanford King Center on Global Development, Stanford University
Universal access to quality, life-saving drugs is a key challenge faced by low-income countries. In 2017, the World Health Organization estimated that about two billion people across the world still lacked access to essential drugs, and that one in ten medicines in circulation in developing countries was of poor quality. It was also estimated that between 2.1 and 4.9 percent of all malaria-related deaths in Sub-Saharan Africa were due to poor quality antimalarials, with severe economic impacts. The local market structure for essential drugs such as antimalarials has been relatively understudied compared with the adverse, potentially fatal, consequences it may have on individuals’ health. What is its role in shaping the availability, price and quality of antimalarials on the market? How does it interact with local infrastructure quality? Based on an empirical approach, the objective of this project is twofold. First, it seeks to better understand the market structure for antimalarial drugs in Sub-Saharan Africa to identify its potential failures. Secondly, it aims at studying spatial heterogeneities in access to quality health products in low-income countries.